HIMS & HERS HEALTH INC (HIMS) Stock Fundamental Analysis
NYSE:HIMS - New York Stock Exchange, Inc. - US4330001060 - Common Stock - Currency: USD
Overall HIMS gets a fundamental rating of 6 out of 10. We evaluated HIMS against 102 industry peers in the Health Care Providers & Services industry. While HIMS has a great health rating, its profitability is only average at the moment. HIMS is valued quite expensively, but it does show have an excellent growth rating. These ratings could make HIMS a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year HIMS was profitable.
HIMS had a positive operating cash flow in the past year.
In the past 5 years HIMS reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: HIMS reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 18.44%, HIMS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of 29.93%, HIMS belongs to the top of the industry, outperforming 95.10% of the companies in the same industry.
HIMS's Return On Invested Capital of 14.93% is amongst the best of the industry. HIMS outperforms 91.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.44% | ||
| ROE | 29.93% | ||
| ROIC | 14.93% |
ROA(3y)-1.82%
ROA(5y)-6.51%
ROE(3y)-0.49%
ROE(5y)-7.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HIMS's Profit Margin of 9.21% is amongst the best of the industry. HIMS outperforms 93.14% of its industry peers.
Looking at the Operating Margin, with a value of 6.48%, HIMS is in the better half of the industry, outperforming 67.65% of the companies in the same industry.
HIMS has a Gross Margin of 77.04%. This is amongst the best in the industry. HIMS outperforms 92.16% of its industry peers.
HIMS's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.48% | ||
| PM (TTM) | 9.21% | ||
| GM | 77.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5YN/A
2. Health
2.1 Basic Checks
HIMS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, HIMS has more shares outstanding
The number of shares outstanding for HIMS has been increased compared to 5 years ago.
There is no outstanding debt for HIMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
HIMS has an Altman-Z score of 24.11. This indicates that HIMS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 24.11, HIMS belongs to the best of the industry, outperforming 98.04% of the companies in the same industry.
There is no outstanding debt for HIMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 24.11 |
ROIC/WACC1.65
WACC9.05%
2.3 Liquidity
A Current Ratio of 1.59 indicates that HIMS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.59, HIMS is in line with its industry, outperforming 56.86% of the companies in the same industry.
A Quick Ratio of 1.32 indicates that HIMS should not have too much problems paying its short term obligations.
HIMS's Quick ratio of 1.32 is in line compared to the rest of the industry. HIMS outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.32 |
3. Growth
3.1 Past
HIMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 7000.00%, which is quite impressive.
The Earnings Per Share has been growing by 60.35% on average over the past years. This is a very strong growth
HIMS shows a strong growth in Revenue. In the last year, the Revenue has grown by 85.99%.
Measured over the past years, HIMS shows a very strong growth in Revenue. The Revenue has been growing by 75.77% on average per year.
EPS 1Y (TTM)7000%
EPS 3YN/A
EPS 5Y60.35%
EPS Q2Q%300%
Revenue 1Y (TTM)85.99%
Revenue growth 3Y75.77%
Revenue growth 5YN/A
Sales Q2Q%110.67%
3.2 Future
Based on estimates for the next years, HIMS will show a very strong growth in Earnings Per Share. The EPS will grow by 41.75% on average per year.
The Revenue is expected to grow by 24.96% on average over the next years. This is a very strong growth
EPS Next Y17.11%
EPS Next 2Y35.57%
EPS Next 3Y35.34%
EPS Next 5Y41.75%
Revenue Next Year60.47%
Revenue Next 2Y38.96%
Revenue Next 3Y32.93%
Revenue Next 5Y24.96%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 80.41, the valuation of HIMS can be described as expensive.
HIMS's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of HIMS to the average of the S&P500 Index (26.31), we can say HIMS is valued expensively.
A Price/Forward Earnings ratio of 55.90 indicates a quite expensive valuation of HIMS.
HIMS's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of HIMS to the average of the S&P500 Index (22.13), we can say HIMS is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 80.41 | ||
| Fwd PE | 55.9 |
4.2 Price Multiples
HIMS's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. HIMS is more expensive than 62.75% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as HIMS.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.51 | ||
| EV/EBITDA | 87.34 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HIMS does not grow enough to justify the current Price/Earnings ratio.
HIMS has a very decent profitability rating, which may justify a higher PE ratio.
HIMS's earnings are expected to grow with 35.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.7
PEG (5Y)1.33
EPS Next 2Y35.57%
EPS Next 3Y35.34%
5. Dividend
5.1 Amount
No dividends for HIMS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
55.48
-1.67 (-2.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners73.96%
Inst Owner Change-2.76%
Ins Owners10.67%
Ins Owner Change-0.19%
Market Cap12.42B
Analysts71
Price Target47.96 (-13.55%)
Short Float %32.67%
Short Ratio1.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.39%
Min EPS beat(2)4.62%
Max EPS beat(2)62.17%
EPS beat(4)4
Avg EPS beat(4)192.83%
Min EPS beat(4)4.62%
Max EPS beat(4)666.87%
EPS beat(8)7
Avg EPS beat(8)156.65%
EPS beat(12)11
Avg EPS beat(12)110.67%
EPS beat(16)12
Avg EPS beat(16)78.36%
Revenue beat(2)2
Avg Revenue beat(2)3.52%
Min Revenue beat(2)0.3%
Max Revenue beat(2)6.75%
Revenue beat(4)4
Avg Revenue beat(4)3.3%
Min Revenue beat(4)0.3%
Max Revenue beat(4)6.75%
Revenue beat(8)6
Avg Revenue beat(8)1.56%
Revenue beat(12)10
Avg Revenue beat(12)2.89%
Revenue beat(16)14
Avg Revenue beat(16)3.76%
PT rev (1m)10.31%
PT rev (3m)11.18%
EPS NQ rev (1m)0.87%
EPS NQ rev (3m)-2.83%
EPS NY rev (1m)0%
EPS NY rev (3m)22.43%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)-2.91%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)3.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 80.41 | ||
| Fwd PE | 55.9 | ||
| P/S | 6.96 | ||
| P/FCF | 52.51 | ||
| P/OCF | 37.14 | ||
| P/B | 22.61 | ||
| P/tB | 32 | ||
| EV/EBITDA | 87.34 |
EPS(TTM)0.69
EY1.24%
EPS(NY)0.99
Fwd EY1.79%
FCF(TTM)1.06
FCFY1.9%
OCF(TTM)1.49
OCFY2.69%
SpS7.97
BVpS2.45
TBVpS1.73
PEG (NY)4.7
PEG (5Y)1.33
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.44% | ||
| ROE | 29.93% | ||
| ROCE | 18.9% | ||
| ROIC | 14.93% | ||
| ROICexc | 31.63% | ||
| ROICexgc | 71.61% | ||
| OM | 6.48% | ||
| PM (TTM) | 9.21% | ||
| GM | 77.04% | ||
| FCFM | 13.25% |
ROA(3y)-1.82%
ROA(5y)-6.51%
ROE(3y)-0.49%
ROE(5y)-7.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5YN/A
F-Score6
Asset Turnover2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 437.46% | ||
| Cap/Sales | 5.48% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 242.39% | ||
| Profit Quality | 143.86% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.32 | ||
| Altman-Z | 24.11 |
F-Score6
WACC9.05%
ROIC/WACC1.65
Cap/Depr(3y)228.03%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7000%
EPS 3YN/A
EPS 5Y60.35%
EPS Q2Q%300%
EPS Next Y17.11%
EPS Next 2Y35.57%
EPS Next 3Y35.34%
EPS Next 5Y41.75%
Revenue 1Y (TTM)85.99%
Revenue growth 3Y75.77%
Revenue growth 5YN/A
Sales Q2Q%110.67%
Revenue Next Year60.47%
Revenue Next 2Y38.96%
Revenue Next 3Y32.93%
Revenue Next 5Y24.96%
EBIT growth 1Y2214.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year366.35%
EBIT Next 3Y97.77%
EBIT Next 5Y66.66%
FCF growth 1Y3973.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14096.9%
OCF growth 3YN/A
OCF growth 5YN/A